Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Christina Finlayson

Concepts (201)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
26
2017
2142
1.010
Why?
Carcinoma, Ductal, Breast
5
2017
82
0.490
Why?
Mastectomy, Segmental
5
2017
85
0.390
Why?
Receptors, Estrogen
7
2012
426
0.340
Why?
Sentinel Lymph Node Biopsy
3
2008
107
0.310
Why?
Lymph Nodes
3
2007
472
0.300
Why?
Thoracic Vertebrae
1
2007
74
0.280
Why?
Prostheses and Implants
1
2007
133
0.260
Why?
Mammography
1
2007
146
0.260
Why?
Receptors, Progesterone
4
2012
343
0.220
Why?
Receptor, ErbB-2
3
2012
326
0.220
Why?
src Homology Domains
1
2003
37
0.220
Why?
Mastectomy
3
2007
131
0.210
Why?
Preoperative Care
2
2001
340
0.200
Why?
Estrogens
3
2012
347
0.190
Why?
Patients
1
2001
167
0.170
Why?
Mammaplasty
1
2001
98
0.170
Why?
Vitamin E
1
2000
120
0.160
Why?
Phytotherapy
1
2000
79
0.160
Why?
Postoperative Hemorrhage
1
2000
87
0.160
Why?
Neoplasm Staging
8
2010
1295
0.150
Why?
Counseling
1
2001
385
0.150
Why?
Reoperation
2
2017
545
0.150
Why?
Tamoxifen
5
2012
200
0.140
Why?
Neoplasms, Radiation-Induced
1
2016
71
0.130
Why?
Pelvic Exenteration
1
1996
11
0.130
Why?
Pelvic Neoplasms
1
1996
19
0.130
Why?
Neoadjuvant Therapy
3
2010
383
0.130
Why?
Neoplasms, Second Primary
1
2016
106
0.120
Why?
Carcinoma, Lobular
2
2017
48
0.120
Why?
Risk Reduction Behavior
1
2016
209
0.120
Why?
Hodgkin Disease
1
2016
134
0.120
Why?
Antineoplastic Agents, Hormonal
4
2012
158
0.110
Why?
Gene Expression Regulation, Neoplastic
3
2010
1356
0.100
Why?
Insulin
1
2003
2326
0.100
Why?
Signal Transduction
3
2012
4925
0.100
Why?
Practice Patterns, Physicians'
2
2017
1266
0.100
Why?
Neoplasms, Hormone-Dependent
1
2012
38
0.100
Why?
Radiotherapy, Adjuvant
3
2008
210
0.100
Why?
Female
23
2017
68776
0.090
Why?
Carcinoma in Situ
1
2011
45
0.090
Why?
Breast
2
2003
153
0.090
Why?
Axilla
2
2007
45
0.090
Why?
Practice Guidelines as Topic
2
2017
1501
0.090
Why?
Keratin-5
1
2010
50
0.080
Why?
Radiotherapy
2
2008
188
0.080
Why?
Middle Aged
14
2017
31154
0.080
Why?
Palliative Care
1
1996
725
0.080
Why?
Estrogen Receptor alpha
1
2010
133
0.080
Why?
BRCA2 Protein
1
2009
53
0.080
Why?
Humans
30
2017
129650
0.080
Why?
Pregnancy Complications, Neoplastic
1
2009
53
0.080
Why?
Thrombophilia
1
2009
81
0.080
Why?
Drug Resistance, Neoplasm
2
2010
759
0.070
Why?
Aromatase Inhibitors
1
2008
51
0.070
Why?
Adjuvants, Immunologic
1
2008
221
0.070
Why?
Radiotherapy Planning, Computer-Assisted
1
2007
124
0.070
Why?
Breast Cyst
1
2006
2
0.070
Why?
Cyst Fluid
1
2006
26
0.070
Why?
Carcinoma, Papillary
1
2007
77
0.070
Why?
Sternum
1
2006
25
0.070
Why?
Biomarkers, Tumor
2
2010
1181
0.060
Why?
Melatonin
1
2006
125
0.060
Why?
Phosphoproteins
2
2008
332
0.060
Why?
Carcinoma, Ductal
1
2005
11
0.060
Why?
Adult
12
2017
35576
0.060
Why?
Ki-67 Antigen
1
2005
109
0.060
Why?
Enzyme Inhibitors
1
2008
827
0.060
Why?
Combined Modality Therapy
4
2008
1206
0.060
Why?
Retroviridae Proteins, Oncogenic
1
2003
10
0.060
Why?
Liver Neoplasms
1
2009
640
0.060
Why?
Oncogene Protein v-akt
1
2003
24
0.050
Why?
Insulin Receptor Substrate Proteins
1
2003
59
0.050
Why?
Bone Neoplasms
1
2006
231
0.050
Why?
Receptor, Insulin
1
2003
99
0.050
Why?
rhoA GTP-Binding Protein
1
2003
89
0.050
Why?
Retrospective Studies
5
2017
14518
0.050
Why?
Multiple Sclerosis
1
2008
436
0.050
Why?
Vascular Endothelial Growth Factor A
1
2005
530
0.050
Why?
Proto-Oncogene Proteins p21(ras)
1
2003
259
0.050
Why?
Urachus
1
2002
1
0.050
Why?
Mitogen-Activated Protein Kinases
1
2003
312
0.050
Why?
Referral and Consultation
1
2007
732
0.050
Why?
Aged
6
2017
22103
0.050
Why?
Neoplasm Recurrence, Local
1
2007
964
0.050
Why?
Prospective Studies
2
2003
7133
0.040
Why?
Tomography, X-Ray Computed
2
2007
2535
0.040
Why?
Mastectomy, Radical
1
2000
2
0.040
Why?
Nurse Anesthetists
1
2000
3
0.040
Why?
Phosphorylation
1
2003
1713
0.040
Why?
Gynecomastia
1
1998
6
0.040
Why?
Urinary Bladder Neoplasms
1
2002
228
0.040
Why?
Cluster Analysis
2
2012
482
0.040
Why?
Immunohistochemistry
3
2008
1698
0.040
Why?
Endocrine System Diseases
1
1998
33
0.040
Why?
Blood Coagulation
1
2000
238
0.040
Why?
Survival Rate
2
2008
1877
0.040
Why?
Oligonucleotide Array Sequence Analysis
2
2012
769
0.040
Why?
Margins of Excision
1
2017
38
0.040
Why?
Apoptosis
2
2010
2503
0.030
Why?
Gene Expression Profiling
3
2008
1706
0.030
Why?
Ultrasonography
1
2000
716
0.030
Why?
Aged, 80 and over
2
2010
7086
0.030
Why?
Estradiol
2
2010
494
0.030
Why?
Quality Indicators, Health Care
1
2017
298
0.030
Why?
Decision Making
1
2001
851
0.030
Why?
Consensus
1
2017
616
0.030
Why?
Lymph Node Excision
2
2009
164
0.030
Why?
Guideline Adherence
1
2017
526
0.030
Why?
Adenocarcinoma
1
2000
898
0.030
Why?
CD24 Antigen
1
2012
20
0.030
Why?
Breast Neoplasms, Male
1
2012
29
0.020
Why?
Patient Selection
1
1996
663
0.020
Why?
Hyaluronan Receptors
1
2012
96
0.020
Why?
Mice, SCID
1
2012
351
0.020
Why?
Tumor Burden
1
2012
286
0.020
Why?
Clinical Trials as Topic
1
1996
1004
0.020
Why?
Colorado
2
2017
4421
0.020
Why?
Cell Line, Tumor
2
2010
3215
0.020
Why?
Mass Screening
1
1998
1149
0.020
Why?
Biopsy, Needle
1
2011
189
0.020
Why?
Mice, Inbred NOD
1
2012
588
0.020
Why?
Tumor Cells, Cultured
1
2012
940
0.020
Why?
Gene Regulatory Networks
1
2012
284
0.020
Why?
Prognosis
2
2009
3794
0.020
Why?
Electrophoresis, Gel, Two-Dimensional
1
2010
110
0.020
Why?
Peptide Mapping
1
2010
63
0.020
Why?
Databases, Protein
1
2010
62
0.020
Why?
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
1
2010
137
0.020
Why?
Xenograft Model Antitumor Assays
1
2012
814
0.020
Why?
Pregnancy Trimester, Second
1
2009
77
0.020
Why?
Observer Variation
1
2010
315
0.020
Why?
Interferon beta-1a
1
2008
12
0.020
Why?
Cyclophosphamide
1
2009
232
0.020
Why?
Glatiramer Acetate
1
2008
18
0.020
Why?
Pregnancy Trimester, First
1
2009
138
0.020
Why?
Apoptosis Regulatory Proteins
1
2009
182
0.020
Why?
Databases as Topic
1
2008
59
0.020
Why?
Perilipin-1
1
2008
16
0.020
Why?
Estrogen Receptor Modulators
1
2008
17
0.020
Why?
Neoplastic Stem Cells
1
2012
380
0.020
Why?
Neoplasm Invasiveness
1
2010
485
0.020
Why?
Interferon-beta
1
2008
89
0.020
Why?
S100 Proteins
1
2008
36
0.020
Why?
Perimenopause
1
2008
60
0.020
Why?
Androstadienes
1
2008
106
0.020
Why?
Doxorubicin
1
2009
325
0.020
Why?
Mastectomy, Modified Radical
1
2007
6
0.020
Why?
SEER Program
1
2008
206
0.020
Why?
Lymphatic Metastasis
1
2008
320
0.020
Why?
In Situ Hybridization, Fluorescence
1
2008
315
0.020
Why?
Selective Estrogen Receptor Modulators
1
2007
27
0.020
Why?
Blotting, Western
1
2010
1205
0.020
Why?
Carcinoma, Intraductal, Noninfiltrating
1
2007
54
0.020
Why?
Dehydroepiandrosterone Sulfate
1
2006
46
0.020
Why?
Mice, Nude
1
2008
683
0.020
Why?
Transcriptome
1
2012
887
0.020
Why?
Epidermal Growth Factor
1
2006
171
0.020
Why?
Neoplasms
1
2000
2470
0.020
Why?
Positron-Emission Tomography
1
2006
288
0.010
Why?
Neoplasm Proteins
1
2007
424
0.010
Why?
Quality of Life
1
1996
2704
0.010
Why?
Patient Care Planning
1
2005
149
0.010
Why?
Transforming Growth Factor beta
1
2006
457
0.010
Why?
Carrier Proteins
1
2008
743
0.010
Why?
Chemotherapy, Adjuvant
1
2005
381
0.010
Why?
Antineoplastic Agents
2
2008
2061
0.010
Why?
Mice
2
2012
16937
0.010
Why?
Proteomics
1
2010
1062
0.010
Why?
Treatment Outcome
1
2017
10230
0.010
Why?
Peptides
1
2008
925
0.010
Why?
Postmenopause
1
2005
351
0.010
Why?
Diagnosis, Differential
1
2007
1434
0.010
Why?
Cell Proliferation
1
2010
2391
0.010
Why?
Umbilicus
1
2002
16
0.010
Why?
Reproducibility of Results
1
2010
3083
0.010
Why?
Abdominal Neoplasms
1
2002
34
0.010
Why?
Phenotype
1
2010
3076
0.010
Why?
Biopsy
1
2005
1097
0.010
Why?
Age Factors
1
2008
3144
0.010
Why?
Liver
1
2009
1839
0.010
Why?
Antineoplastic Combined Chemotherapy Protocols
1
2009
1565
0.010
Why?
United States
1
2017
13903
0.010
Why?
Hospitals, Private
1
1999
12
0.010
Why?
Hospitals, County
1
1999
10
0.010
Why?
Male
4
2012
63681
0.010
Why?
Receptors, Tumor Necrosis Factor
1
2000
161
0.010
Why?
Hospitals, University
1
1999
179
0.010
Why?
Leydig Cell Tumor
1
1998
7
0.010
Why?
Animals
2
2012
35361
0.010
Why?
Infant, Newborn
1
2009
5762
0.010
Why?
Testicular Neoplasms
1
1998
104
0.010
Why?
Pregnancy
1
2009
6402
0.010
Why?
NF-kappa B
1
2000
653
0.010
Why?
Cost-Benefit Analysis
1
1998
569
0.010
Why?
Socioeconomic Factors
1
1999
1214
0.010
Why?
Tumor Necrosis Factor-alpha
1
2000
1198
0.010
Why?
Patient Education as Topic
1
1999
743
0.010
Why?
Risk Factors
1
2008
9765
0.010
Why?
Models, Biological
1
2000
1722
0.010
Why?
Adolescent
1
1998
20393
0.000
Why?
Finlayson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)